Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Reusing medical equipment is good for the planet. But is it safe?

Benefits of modern hybrid multicloud platforms in health care

Faster acute kidney injury test in development

Free, nurse-led support line for primary liver cancer now open

Updated guidance for telehealth and virtual care now available

Partnership to turn cooking oil into fuel

Why Australia's AI ambitions depend on smarter networks

Nanofiltration membrane tech removes pharma pollution

Sustainability Victoria marks 20 years

Sustainability reporting is here — but confidence in data isn't

Mondi develops lighter banana box

Food quality testing laboratory being opened in Victoria

Getting the right balance of water content in butter

What's on trend in the food supplements & nutrition market?

New standard for edible bird's nest products

Lonza bone marrow and cord blood mononuclear cells

Bioss In Vivo Biosimilar Antibodies

LSBio virology research products

Beckman Coulter Life Sciences IR820 and IR870 infrared dye antibody conjugates

Content from other channels on our network